Compare CTOS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTOS | RAPP |
|---|---|---|
| Founded | 1988 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2017 | 2024 |
| Metric | CTOS | RAPP |
|---|---|---|
| Price | $9.18 | $33.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.30 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 766.5K | 387.9K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,943,957,000.00 | N/A |
| Revenue This Year | $6.84 | N/A |
| Revenue Next Year | $4.86 | N/A |
| P/E Ratio | $310.33 | ★ N/A |
| Revenue Growth | ★ 7.86 | N/A |
| 52 Week Low | $5.18 | $23.75 |
| 52 Week High | $12.23 | $52.93 |
| Indicator | CTOS | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 24.40 |
| Support Level | $9.06 | $26.08 |
| Resistance Level | $9.50 | $40.61 |
| Average True Range (ATR) | 0.28 | 2.53 |
| MACD | 0.06 | -1.12 |
| Stochastic Oscillator | 49.79 | 10.06 |
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.